The Role of 5-HT2A Receptor in the Perception of Self and Personal Meaning in Healthy Volunteers

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

NA

Total Enrollment

25 participants

Study Classification

INTERVENTIONAL

Study Start Date

2015-03-31

Study Completion Date

2016-01-31

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

Aim of the present study is to investigate the neuronal correlates of self and of personal meaning as well as the role of the serotonin (5-HT) 2A receptor system in these processes using functional magnetic resonance imaging (fMRI) and psychometric and cognitive measures.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Neuronal Correlates of Altered States of Consciousness

NCT02308969

Healthy

COMPLETED EARLY_PHASE1

Role of Dopamine, Serotonin and 5-HT2A Receptors in Emotion Processing

NCT03019822

Healthy

COMPLETED EARLY_PHASE1

Characterization of Altered Waking States of Consciousness in Healthy Humans

NCT03853577

Altered Waking States of Consciousness in Healthy Humans

COMPLETED NA

Brain Function and EEG

NCT05003076

Healthy Mood

COMPLETED EARLY_PHASE1

Time,Self and Spontaneous Mental Activities in Patients With Psychotic Disorders

NCT02765880

Schizophrenia Bipolar Disorder

TERMINATED NA

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

The present study aims at identifying the contribution of the 5-HT2A receptor system to the formation of self and personal meaning in normal and altered states of consciousness. Specifically, the effect of the 5-HT2/1/6/7 receptor agonist lysergic acid diethylamide (LSD) on self-consciousness, perception and the making of meaning will be assessed in 25 healthy subjects using a randomized, placebo-controlled, double blind, cross-over design. Furthermore, the contribution of the 5-HT2A receptor to these functions shall be assessed by pretreatment with the specific 5-HT2A antagonist ketanserin.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

BASIC_SCIENCE

Blinding Strategy

DOUBLE

Participants Investigators

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Placebo, LSD, Ketanserin/LSD

Cross-over within-subjects design with all treatment conditions tested in the same subject. This design has 1 arm but three treatment conditions in the same subject

Group Type EXPERIMENTAL

Placebo

Intervention Type DRUG

Capsules containing mannitol looking identical to LSD per os

LSD

Intervention Type DRUG

100µg per os, single dose

Ketanserin

Intervention Type DRUG

40mg per os, single dose looking identical to LSD per os

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

Placebo

Capsules containing mannitol looking identical to LSD per os

Intervention Type DRUG

LSD

100µg per os, single dose

Intervention Type DRUG

Ketanserin

40mg per os, single dose looking identical to LSD per os

Intervention Type DRUG

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

Lysergic acid diethylamide Sufrexal

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Healthy male and female volunteers at the age of 20-40
* Willing and capable to give informed consent for study participation as documented by signature after the nature of the study has been thoroughly explained
* Willing to refrain from drinking alcohol the day before testing session, from drinking alcohol and caffeinated drinks at the testing days and from consuming psychoactive substances 2 weeks before testing days and for the duration of the study
* Able and willing to comply with all study requirements
* MRI-compatible body shape and size (Body mass index \[BMI\] 17-30)
* Right-handedness

Exclusion Criteria

* Poor knowledge of the German language
* Previous significant adverse response to a hallucinogenic drug
* Participation in another study where pharmaceutical compounds are given within the 30 days preceding and during the present study
* Self or first-degree relatives with present or antecedent psychiatric disorders
* Present or antecedent alcohol/drug dependence or present alcohol/drug abuse
* History of head trauma, fainting, seizures, or electroconvulsive therapy
* Recent cardiac or brain surgery
* Current use of medication known to affect brain function (e.g. benzodiazepines, antihistamines, aspirin, beta blockers, theophylline, acetazolamide, etc.)
* Concomitant therapy with potent inhibitors of cytochrome P-450 isoenzyme 3A4 (HIV protease inhibitors, macrolide antibiotics, acylderivative anti-infective agents)
* Presence of major internal or neurological disorders (including sepsis, pheochromocytoma, thyrotoxicosis, drug-induced fibrosis, familiar or basilar artery migraine)
* Presence of psychiatric disorder
* Cardiovascular disease (hypertonia, coronary artery disease, heart insufficiency, myocardial infarction within the past 6 months, coronary spastic angina)
* Peripheral vascular disease (thromboangiitis obliterans, luetic arteritis, severe arteriosclerosis, thrombophlebitis, Raynaud's disease)
* Liver or renal disease
* Pregnant or breastfeeding women (a urine pregnancy test will be done before each session for all women capable of bearing children)
* Inability to lie still for about 60 minutes (e.g. because of sneezing, itching, tremor, pain)
* Metal parts in the body (piercings, brain aneurysm clip, implanted neural stimulator/cardiac pacemaker/defibrillator/Swan Ganz catheter/insulin pump, cochlear implant); metal shrapnel or bullet, ocular foreign body (e.g. metal shavings); current or previous job in metalworking industry
* Claustrophobia

Minimum Eligible Age

20 Years

Maximum Eligible Age

40 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes